Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: Expected variations in clearance

Clinical Pharmacokinetics

Volumn 50, Issue 12, 2011, Pages 809-822

  Ghobadi, Cyrus ^a   Johnson, Trevor N ^a   Aarabi, Mohsen ^a   Almond, Lisa M ^a   Allabi, Aurel Constant ^a   Rowland Yeo, Karen ^a   Jamei, Masoud ^a   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alprazolam; Caffeine; Chlorzoxazone; Ciclosporin; Dose prediction; Metabolic clearance rate; Midazolam; Obesity; Pharmacokinetic modelling; Phenytoin; Theophylline; Triazolam

Indexed keywords

ALPRAZOLAM; CAFFEINE; CHLORZOXAZONE; CYCLOSPORIN A; MIDAZOLAM; PHENYTOIN; THEOPHYLLINE; TRIAZOLAM;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEAN BODY WEIGHT; LIVER CLEARANCE; MALE; MORBID OBESITY; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIMULATION;

ADOLESCENT; ADULT; AGED; BENZODIAZEPINES; BODY WEIGHTS AND MEASURES; CAFFEINE; CHLORZOXAZONE; COMPUTER SIMULATION; CYCLOSPORINE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY; OBESITY, MORBID; PHARMACOKINETICS; PHENYTOIN; REGIONAL BLOOD FLOW; THEOPHYLLINE; YOUNG ADULT;

EID: 81255189066     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11594420-000000000-00000     Document Type: Article

References (115)

1. Williams JA, JohnsonK, Paulauskis J, et al. So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 2006 Mar; 46 (3): 258-64 (Pubitemid 43260312)
2. Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. London: Wiley, 2007
3. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998 Apr; 26 (2): 207-46 (Pubitemid 28496599)
4. Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008 Sep; 4 (9): 1143-52
5. Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010 Mar 1; 49 (3): 189-206
6. Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: ameta-analysis. Liver Transpl 2005 Dec; 11 (12): 1481-93 (Pubitemid 43072624)
7. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45 (9): 931-56 (Pubitemid 44299829)
8. World Health Organization. Obesity and overweight [fact sheet no. 311; online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs311/en/ index.html [Accessed 2011 Oct 7]
9. Mingfang L, Cheung BMY. Pharmacotherapy for obesity. Br J Clin Pharmacol 2009; 68 (6): 804-10
10. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981 Nov-Dec; 6 (6): 429-53 (Pubitemid 12213270)
11. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000 Sep; 39 (3): 215-31
12. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49 (2): 71-87
13. Atkinson Jr AJ, Lyster PM. Systems clinical pharmacology. Clin Pharmacol Ther 2010 Jul; 88 (1): 3-6
14. Gibson GG, Rostami-Hodjegan A. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica 2007 Oct-Nov; 37 (10-11): 1013-4
15. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004 Aug; 58 (2): 119-33 (Pubitemid 39043992)
16. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998 Oct; 54 (8): 621-5 (Pubitemid 28531423)
17. Traynor AM, Nafziger AN, Bertino Jr JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995 Feb; 39 (2): 545-8
18. Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of betaadrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997 Jun; 43 (6): 563-70 (Pubitemid 27283564)
19. Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance [letter]. Clin Pharmacol Ther 2009 Jan; 85 (1): 23; author reply 24
20. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24 (1): 53-75
21. Jamei M, Marciniak S, Feng K, et al. The Simcyp-Population-Based ADME Simulator. Expert Opin Drug Metab Toxicol 2009 Feb; 5 (2): 211-23
22. Rostami-Hodjegan A, Tucker GT. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today Technol 2004; 1: 441-8 (Pubitemid 40186348)
23. Howgate EM, Rowland-Yeo K, Proctor NJ, et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 2006 Jun; 36 (6): 473-97 (Pubitemid 43890728)
24. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975 Oct; 18 (4): 377-90
25. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. AdvDrug Deliv Rev 2001 Oct 1; 50 Suppl. 1: S41-67 (Pubitemid 32905355)
26. Jamei M, TurnerD, Yang J, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009 Jun; 11 (2): 225-37
27. Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity [letter]. Hepatology 2002 Jun; 35 (6): 1549-50; author reply 1550-1
28. Gertz M, Harrison A, Houston JB, et al. Prediction of human intestinal firstpass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 2010 Jul; 38 (7): 1147-58
29. Yang J, Jamei M, Yeo KR, et al. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007 Oct; 8 (7): 676-84 (Pubitemid 47578116)
30. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253
31. De Lorenzo A, Deurenberg P, Pietrantuono M, et al. How fat is obese? Acta Diabetol 2003 Oct; 40 Suppl. 1: S254-7 (Pubitemid 37322768)
32. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17: 863-71
33. Verbraecken J, Van de Heyning P, De Backer W, et al. Body surface area in normal-weight, overweight, and obese adults: a comparison study. Metabolism 2006 Apr; 55 (4): 515-24
34. Yu CY, Lo YH, Chiou WK. The 3Dscanner for measuring body surface area: a simplified calculation in the Chinese adult. Appl Ergon 2003 May; 34 (3): 273-8
35. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987 Oct 22; 317 (17): 1098
36. Boyd E. The growth of the surface area of the human body. Minneapolis (MN): University of Minnesota Press, 1935
37. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970 Aug; 54 (4): 225-35
38. Anderson E, Browne N, Duketsky S, et al. Development of statistical distributions or ranges of standard factors used in exposure assessments: final report [report no. EPA/600/8-85-010].Washington, DC: US Environmental Protection Agency, 1985 [online]. Available from URL: http://www.epa. gov/opptintr/ exposure/pubs/usepa-1985b-development-of-statistical-distri butions.pdf [Accessed 2011 Sep 22]
39. Haycock GB, Schwartz GJ,Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978 Jul; 93 (1): 62-6 (Pubitemid 8351870)
40. Mattar JA.Asimple calculation to estimate body surface area in adults and its correlation with the Du Bois formula. Crit Care Med 1989; 17: 846-7
41. Livingston EH, Lee S. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001 Sep; 281 (3): E586-91
42. Colles SL,Dixon JB,Marks P, et al. Preoperative weight loss with a very-lowenergy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 2006 Aug; 84 (2): 304-11 (Pubitemid 44699138)
43. Vasan RS. Cardiac function and obesity. Heart 2003 Oct; 89 (10): 1127-9 (Pubitemid 37163991)
44. Collis T, Devereux RB, Roman MJ, et al. Relations of stroke volume and cardiac output to body composition: the Strong Heart Study. Circulation 2001 Feb 13; 103 (6): 820-5 (Pubitemid 32163879)
45. de Simone G, Devereux RB, Daniels SR, et al. Stroke volume and cardiac output in normotensive children and adults: assessment of relations with body size and impact of overweight. Circulation 1997 Apr 1; 95 (7): 1837-43 (Pubitemid 27164401)
46. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981 Jan; 141 (1): 81-5 (Pubitemid 11100827)
47. Messerli FH, Sundgaard-Riise K, Reisin E, et al. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983 May; 74 (5): 808-12 (Pubitemid 13080124)
48. SalvadoriA, Fanari P, FontanaM, et al.Oxygen uptake and cardiac performance in obese and normal subjects during exercise. Respiration 1999; 66 (1): 25-33 (Pubitemid 29089989)
49. Stelfox HT, Ahmed SB, Ribeiro RA, et al. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006 Apr; 34 (4): 1243-6
50. Taylor HL, Brozek J, Keys A. Basal cardiac function and body composition with special reference to obesity. J Clin Invest 1952 Nov; 31 (11): 976-83
51. Jegier W, Sekelj P, Auld PA, et al. The relation between cardiac output and body size. Br Heart J 1963 Jul; 25: 425-30
52. Abernethy DR, Greenblatt DJ,Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984 Mar-Apr; 9 (2): 177-83 (Pubitemid 14164708)
53. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm 1987 Sep; 6 (9): 706-14 (Pubitemid 17152549)
54. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007 Jan; 8 (1): 33-45 (Pubitemid 46043890)
55. Barter ZE, Chowdry JE, Harlow JR, et al. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 2008 Dec; 36 (12): 2405-9
56. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999 Jan; 37 (1): 8-19 (Pubitemid 29043392)
57. Caraco Y, Zylber-Katz E, Berry EM, et al. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther 1992 May; 51 (5): 501-6
58. Caraco Y, Zylber-Katz E, Berry EM, et al. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 1995 Sep; 29 (9): 843-7
59. Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991 May; 49 (5): 536-49
60. Flechner SM, Kolbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 1989 May; 47 (5): 806-10 (Pubitemid 19139118)
61. Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984 Jul; 61 (1): 27-35 (Pubitemid 14089351)
62. Bentley JB, Vaughan RW, Gandolfi AJ, et al. Halothane biotransformation in obese and nonobese patients. Anesthesiology 1982 Aug; 57 (2): 94-7 (Pubitemid 12041004)
63. Bentley JB, Vaughan RW, Miller MS, et al. Serum inorganic fluoride levels in obese patients during and after enflurane anesthesia. Anesth Analg 1979 Sep-Oct; 58 (5): 409-12 (Pubitemid 10226203)
64. Frink Jr EJ, Malan Jr TP, Brown EA, et al. Plasma inorganic fluoride levels with sevoflurane anesthesia in morbidly obese and nonobese patients. Anesth Analg 1993 Jun; 76 (6): 1333-7 (Pubitemid 23164089)
65. HiguchiH, Satoh T,Arimura S, et al. Serum inorganic fluoride levels in mildly obese patients during and after sevoflurane anesthesia. Anesth Analg 1993 Nov; 77 (5): 1018-21 (Pubitemid 23319803)
66. Miller MS, Gandolfi AJ, Vaughan RW, et al. Disposition of enflurane in obese patients. J Pharmacol Exp Ther 1980 Nov; 215 (2): 292-6
67. O'Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994 Oct; 56 (4): 359-67 (Pubitemid 24339082)
68. Young SR, Stoelting RK, Peterson C, et al. Anesthetic biotransformation and renal function in obese patients during and after methoxyflurane or halothane anesthesia. Anesthesiology 1975 Apr; 42 (4): 451-7
69. Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984 Dec; 18 (6): 941-6 (Pubitemid 15190533)
70. Benedek IH, Fiske 3rd WD, Griffen WO, et al. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.Br J Clin Pharmacol 1983Dec; 16 (6): 751-4 (Pubitemid 14208224)
71. Sola E, Vaya A, Contreras T, et al. Rheological profile in severe and morbid obesity: preliminary results. Clin HemorheolMicrocirc 2004; 30 (3-4): 415-8 (Pubitemid 38951537)
72. Kasiske BL, Umen AJ. The influence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol Lab Med 1986 Jan; 110 (1): 55-60 (Pubitemid 16011812)
73. Lokkegaard N, Haupter I, Kristensen TB. Microalbuminuria in obesity. Scand J Urol Nephrol 1992; 26 (3): 275-8
74. Naeye RL, Roode P. The sizes and numbers of cells in visceral organs in human obesity. Am J Clin Pathol 1970 Aug; 54 (2): 251-3
75. Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992 Feb; 232 (2): 194-201
76. Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33 (5): 469-503 (Pubitemid 37268185)
77. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
78. Spruill WJ, Wade WE, Cobb 3rd HH. Estimating glomerular filtration rate with a Modification of Diet in Renal Disease equation: implications for pharmacy. Am J Health Syst Pharm 2007 Mar 15; 64 (6): 652-60 (Pubitemid 46481868)
79. Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009 Jul; 54 (1): 33-42
80. British National Formulary. Principles of dose adjustment in renal impairment [online]. Available from URL: http://bnf.org/bnf/bnf/current/43768. htm [Accessed 2011 Jun]
81. Center for Drug Evaluation and Research, US FDA. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm072127.pdf [Accessed 2011 Sep 20]
82. Dionne RE, Bauer LA, Gibson GA, et al. Estimating creatinine clearance in morbidity obese patients. Am J Hosp Pharm 1981 Jun; 38 (6): 841-4
83. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988 Jun; 84 (6): 1053-60
84. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009 Apr 1; 66 (7): 642-8
85. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007 Nov; 82 (5): 505-8 (Pubitemid 47622534)
86. Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000 Jun; 35 (6): 1144-8 (Pubitemid 30354419)
87. Bosma RJ, Krikken JA, Homan van der Heide JJ, et al. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184-202 (Pubitemid 44298232)
88. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003 Jun; 14 (6): 1480-6 (Pubitemid 36687049)
89. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000 May; 278 (5): F817-22 (Pubitemid 30351084)
90. Kotchen TA, Piering AW, Cowley AW, et al. Glomerular hyperfiltration in hypertensive African Americans. Hypertension 2000 Mar; 35 (3): 822-6 (Pubitemid 30165332)
91. Scaglione R, Ganguzza A, Corrao S, et al. Central obesity and hypertension: pathophysiologic role of renal haemodynamics and function. Int J Obes Relat Metab Disord 1995 Jun; 19 (6): 403-9
92. Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005 Aug; 46 (2): 233-41 (Pubitemid 41040351)
93. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol 2001 Jan; 37 (1): 169-74 (Pubitemid 32051734)
94. WangZ,Hall SD, Maya JF, et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003 Jan; 55 (1): 77-85 (Pubitemid 36110842)
95. Caraco Y, Zylber-Katz E, Berry EM, et al. Caffeine pharmacokinetics in obesity and following significant weight reduction. Int J Obes Relat Metab Disord 1995 Apr; 19 (4): 234-9
96. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol 1985 Jul; 20 (1): 61-6 (Pubitemid 15229457)
97. Gal P, Jusko WJ, Yurchak AM, et al. Theophylline disposition in obesity. Clin Pharmacol Ther 1978 Apr; 23 (4): 438-44 (Pubitemid 8327807)
98. Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity: determination of loading dose. Arch Neurol 1985 May; 42 (5): 468-71 (Pubitemid 15113012)
99. Aitchison J, Brown JAC. The lognormal distribution. Cambridge: University Press, 1966
100. Armitage P, Matthews JNS, Berry G. Statistical methods in medical research. 4th ed. New York: Wiley Blackwell, 2001
101. Guest EJ, Aarons L, Houston JB, et al. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos 2011 Feb; 39 (2): 170-3
102. Busetto L, Tregnaghi A, De Marchi F, et al. Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding. Obes Res 2002 May; 10 (5): 408-11 (Pubitemid 135688252)
103. Lewis MC, Phillips ML, Slavotinek JP, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg 2006 Jun; 16 (6): 697-701 (Pubitemid 43874822)
104. Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume inWestern adults. Liver Transpl 2002 Mar; 8 (3): 233-40 (Pubitemid 34257205)
105. Khemawoot P, Yokogawa K, Shimada T, et al. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats. Biochem Pharmacol 2007 Jan 1; 73 (1): 155-62 (Pubitemid 44853929)
106. Cubitt HE, Yeo KR, Howgate EM, et al. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 2011 Aug; 41 (8); 623-38
107. Einolf HJ. Comparison of different approaches to predict metabolic drugdrug interactions. Xenobiotica 2007 Oct-Nov; 37 (10-11): 1257-94 (Pubitemid 350035530)
108. Polasek TM, Polak S, Doogue MP, et al. Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol 2009; 65 (12): 1203-10
109. Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43 (15): 1167-78 (Pubitemid 40013182)
110. Alexander JK, Dennis EW, Smith WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962 Winter; 1: 39-44
111. Bucolo RJ. Obesity, hyperinsulinemia, and portal blood flow: a theoretic study of the effects of increased portal blood flow upon fasting peripheral insulin concentrations. Diabetes 1978 Aug; 27 (8): 840-8 (Pubitemid 9001618)
112. Burton M, Shaw L, Schentag JJ, et al. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Baltimore (MD): Lippincott Williams and Wilkins, 2005
113. Ferreira I, Snijder MB, Twisk JW, et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and Health Longitudinal Study. J Clin Endocrinol Metab 2004 Jun; 89 (6): 2632-9 (Pubitemid 38766342)
114. Pinto-Sietsma SJ, NavisG, Janssen WM, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003 Apr; 41 (4): 733-41
115. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scienti fic-guideline/2009/09/WC500003122.pdf [Accessed 2011 Sep 20]